A new in vitro lung cancer diagnostic test has been launched
by Roche Diagnostics to provide improved detection of cancer.
The first in vitro diagnostic immunohistochemistry (IHC)
assay to provide a cost-effective and efficient way to initially detect
elevated ROS1 protein expression in cancer has been launched. The VENTANA ROS1
(SP384) Rabbit Monoclonal Primary Antibody may also be applied in
identification of ROS1-positive lung cancer.
Mutations of the ROS1 gene are present in some non-small
cell lung cancer (NSCLC). These can help to discover which patients would
respond to targeted treatment.
“Our highly sensitive ROS1 test is the first in vitro
diagnostic test available for recommended lung cancer testing guidelines, with
the added benefit of rapid turnaround time,†said Pierre Hazlewood, marketing
director at Roche Diagnostics, who launched the test.
These types of cancer are rare and only found in up to 2
percent of NSCLC cases. This means the treatment will provide a cost-effective
and efficient way to pinpoint cases of elevated ROS1 protein expression. This
can indicate which method to use next, such as fluorescence in situ
hybridisation (FISH) or next generation sequencing (NGS).
Guidelines from the College of American Pathologists and the
National Comprehensive Cancer Network, US, recommend ROS1 testing for confirmed
lung adenocarcinoma cases.
Source: https://www.drugtargetreview.com/news/44771/first-in-vitro-lung-cancer-test-launched/
.png)
.jpg)
.gif)
